Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day
March 19 2015 - 08:00AM
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that
Chief Operating Officer, Dr. Niranjan Sardesai, will present at the
3rd Annual Regen Med Investor Day to be held Wednesday, March 25,
2015 at the Metropolitan Club in New York City.
Dr. Sardesai's presentation will begin at 4:05 PM ET. A
live-streaming webcast of all panels and company presentations,
including Dr. Sardesai's, will be available at:
http://www.arminvestorday.com/webcast. The live and archived
version of the event (to be made available upon completion of the
conference) will also be available through the "Webcast" tab on
Inovio's home page at www.inovio.com.
Organized by the Alliance for Regenerative Medicine and
co-hosted by Piper Jaffray, the Regen Med Investor Day provides
institutional, strategic and venture investors with unique insight
into the financing hypothesis for advanced therapies-based
treatment and tools. The program includes clinical and commercial
experts who will address specific questions regarding the outlook
for these products as well as offer insight into how advanced
therapies could impact the standard of care in key therapeutic
areas. In addition to presentations by more than 30 companies from
across the globe, this event includes interactive panels featuring
research analysts covering the space, key clinical opinion leaders,
and top company CEOs.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania, DARPA, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com.
This press release contains certain forward-looking statements
relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, including INO-5150, and
to commence a phase I clinical trial for INO-5150 in the first half
of 2015, the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2014,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals,
858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals,
267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2023 to Mar 2024